Progyny, Inc. (NASDAQ:PGNY - Get Free Report) hit a new 52-week high during trading on Wednesday. The company traded as high as $37.21 and last traded at $36.2850, with a volume of 35,270 shares. The stock had previously closed at $36.71.
Wall Street Analyst Weigh In
Several research firms have weighed in on PGNY. Wall Street Zen raised Progyny from a "buy" rating to a "strong-buy" rating in a research note on Sunday, November 8th. Canaccord Genuity Group set a $35.00 target price on shares of Progyny in a research note on Friday, August 7th. Zacks Research downgraded shares of Progyny from a "strong-buy" rating to a "hold" rating in a report on Monday, October 19th. BTIG Research raised their target price on shares of Progyny from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, July 24th. Finally, JPMorgan Chase & Co. boosted their price target on Progyny from $30.00 to $35.00 and gave the company a "neutral" rating in a research note on Monday, November 9th. Eleven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $35.83.
View Our Latest Research Report on Progyny
Progyny Stock Performance
The firm has a market cap of $2.69 billion, a price-to-earnings ratio of 33.47, a price-to-earnings-growth ratio of 1.70 and a beta of 0.97. The stock has a 50-day moving average of $28.90 and a 200-day moving average of $25.00.
Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.21. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The firm had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. During the same period in the prior year, the firm posted $0.15 earnings per share. The company's quarterly revenue was up 8.9% compared to the same quarter last year. Sell-side analysts predict that Progyny, Inc. will post 1.43 EPS for the current fiscal year.
Insiders Place Their Bets
In other Progyny news, Director Kevin K. Gordon sold 11,500 shares of the company's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the completion of the transaction, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. This represents a 62.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Mark S. Livingston sold 2,139 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $30.00, for a total value of $64,170.00. Following the transaction, the chief financial officer owned 70,314 shares in the company, valued at $2,109,420. The trade was a 2.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 630,072 shares of company stock valued at $22,363,084 over the last 90 days. 9.90% of the stock is owned by company insiders.
Institutional Trading of Progyny
Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in Progyny in the second quarter worth $334,426,000. Bank of America Corp DE lifted its position in shares of Progyny by 75.3% during the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company's stock valued at $20,223,000 after buying an additional 511,609 shares during the last quarter. William Blair Investment Management LLC purchased a new stake in Progyny during the 2nd quarter worth approximately $16,807,000. Danske Bank A S acquired a new position in shares of Progyny in the 2nd quarter valued at $15,243,000. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Progyny by 23.3% in the third quarter. Goldman Sachs Group Inc. now owns 530,279 shares of the company's stock valued at $13,358,000 after purchasing an additional 100,335 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.
About Progyny
(
Get Free Report)
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company's offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.